What can we learn from design faults in the women's health initiative randomized clinical trial?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 67, Issue 2, 2009, Pages 226-229

  Tan, Orkun ^a   Harman, S Mitchell ^b   Naftolin, Frederick ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kronos Longevity Research Institute   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; HAZARD RATIO; HEALTH CARE FACILITY; HEALTH PRACTITIONER; HEALTH SERVICE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MENOPAUSE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; WOMEN'S HEALTH;

AGE FACTORS; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; COMPREHENSION; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SELECTION BIAS; TIME FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 67649472801     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
2. The Women's Health Initiative Steering Committee, effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333 (Pubitemid 34761611)
4. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004 Jun;81(6):1498-1501
5. Mikkola S, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605-619 (Pubitemid 34175253)
6. Haynes MP, Li L, Russell KS, Bender JR. Rapid vascular cell responses to estrogen and membrane receptors. Vasc Pharmacol. 2002;38:99-108. (Pubitemid 36401587)
7. Diano S, Horvath TL, Mor G, et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and humans. Menopause. 1999;6:21-28 (Pubitemid 29131755)
8. Raggi P, Khan A, Arepali C, Stillman AE. Coronary artery calcium scoring in the age of CT angiography: what is its role? Cuff Atheroscler Rep. 2008 Oct;10(5):438-443
9. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762
10. Langer RD. Legend meets reality: estrogen plus progestin and coronary heart disease in the Women's Health Initiative. Menopausal Med. 2003;10:5-7.
11. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854 (Pubitemid 36532310)
12. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991 Sep 12;325(11):756-762
13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534 (Pubitemid 36951364)
14. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28;289(20):2651-2662
15. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15:584-602.
16. Naftolin F, Schneider HP, Sturdee DW. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric. 2004;7:8-11.
17. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15:35-44. (Pubitemid 43192860)
18. Brinton EA, Hodis HN, Merriam GR, et al. Can menopausal hormone therapy prevent coronary heart diseases? Trends Endocrinol Metab. 2008;19:206-212